We are live on
!
Find out more
ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
1-Year Est. Return
7.38%
This Fund
S&P 500
This Quarter
Est. Return
-2.69%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$195M
AUM Growth
-$51.6M
(-21%)
Cap. Flow
-$43.8M
Cap. Flow
% of AUM
-22.51%
Top 10 Holdings %
Top 10 Hldgs %
61.32%
Holding
72
New
17
Increased
14
Reduced
19
Closed
22
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$17.8M |
| 2 |
Becton Dickinson
BDX
|
+$17.1M |
| 3 |
Sabra Healthcare REIT
SBRA
|
+$9.02M |
| 4 |
Teva Pharmaceuticals
TEVA
|
+$7.54M |
| 5 |
Qiagen
QGEN
|
+$6.63M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Labcorp
LH
|
+$10.9M |
| 2 |
Centene
CNC
|
+$9.85M |
| 3 |
Merck
MRK
|
+$8.25M |
| 4 |
Icon
ICLR
|
+$7.14M |
| 5 |
Cigna
CI
|
+$6.37M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.97% |
| 2 | Real Estate | 8.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Thermo Fisher Scientific
TMO
$214B
| $2.16M | 1.11% |
3,744
+2,155
| +136% | +$1.21M |
|
|
27
Centene
CNC
$31.7B
| $1.87M | 0.96% |
29,586
-138,777
| -82% | -$9.85M |
|
|
ADAP
28
DELISTED
Adaptimmune Therapeutics
ADAP
| $1.81M | 0.93% |
1,660,835
-72,401
| -4% | -$112K |
|
|
BLUE
29
DELISTED
bluebird bio
BLUE
| $1.67M | 0.86% |
+26,253
| New | +$3M |
|
|
ISEE
30
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $1.57M | 0.81% |
+64,704
| New | +$1.42M |
|
|
GRTS
31
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $1.5M | 0.77% |
540,657
+257,722
| +91% | +$736K |
|
32
Cencora
COR
$63.2B
| $1.47M | 0.75% |
9,153
-11,881
| -56% | -$1.88M |
|
33
Encompass Health
EHC
$12.4B
| $1.43M | 0.74% |
26,471
-51,673
| -66% | -$3.01M |
|
34
uniQure
QURE
$3.15B
| $1.43M | 0.73% |
+71,040
| New | +$1.49M |
|
35
Zoetis
ZTS
$32.4B
| $1.4M | 0.72% |
8,414
-8,314
| -50% | -$1.36M |
|
36
Baxter International
BAX
$14B
| $1.4M | 0.72% |
34,508
+23,500
| +213% | +$996K |
|
37
ResMed
RMD
$32.4B
| $1.39M | 0.71% |
+6,345
| New | +$1.38M |
|
38
Zimmer Biomet
ZBH
$18.8B
| $1.2M | 0.62% |
+9,283
| New | +$1.17M |
|
39
Viking Therapeutics
VKTX
$3.88B
| $950K | 0.49% |
57,043
-375,992
| -87% | -$3.88M |
|
40
Aclaris Therapeutics
ACRS
$851M
| $679K | 0.35% |
+83,891
| New | +$1.06M |
|
|
CTLT
41
DELISTED
CATALENT, INC.
CTLT
| $601K | 0.31% |
9,144
-26,121
| -74% | -$1.61M |
|
42
Iovance Biotherapeutics
IOVA
$2.77B
| $492K | 0.25% |
80,455
+9,800
| +14% | +$67.6K |
|
43
Coherus Oncology
CHRS
$194M
| $444K | 0.23% |
+64,956
| New | +$504K |
|
|
ETNB
44
DELISTED
89bio
ETNB
| $298K | 0.15% |
19,585
-17,199
| -47% | -$224K |
|
45
Maravai LifeSciences
MRVI
$922M
| $291K | 0.15% |
20,753
-705
| -3% | -$10.1K |
|
46
BioXcel Therapeutics
BTAI
$25.6M
| $217K | 0.11% |
+728
| New | +$311K |
|
47
Biodesix
BDSX
$229M
| $211K | 0.11% |
5,663
-559
| -9% | -$22.9K |
|
|
ADXN
48
Addex Therapeutics
ADXN
$7.34M
| $114K | 0.06% |
+6,037
| New | +$153K |
|
|
ATNX
49
DELISTED
Athenex, Inc. Common Stock
ATNX
| $56.7K | 0.03% |
42,651
-2,461
| -5% | -$7.29K |
|
|
50
CALL
Viking Therapeutics
VKTX
$3.88B
| $7.36K | ﹤0.01% |
+442
| New | +$4.57K |
|
Similar funds
VAFP
CA
SCM
FWM
TOPU
CCMU
TGI
HSCU
Endurant Capital Management's Q1 2023 Portfolio in Review
As of Q1 2023, Endurant Capital Management held 72 positions worth $195M, down 21% from $246M the previous quarter. Its ten largest holdings account for 61% of the portfolio.
Endurant Capital Management withdrew a net $43.8M in Q1 2023, closing 22 positions and reducing 19 holdings. Its most notable exit was Elutia, an estimated $5.35M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 74% a quarter earlier, followed by Real Estate.
Against the trend, Endurant Capital Management opened a new position in Teva Pharmaceuticals worth $6.75M.
- Endurant Capital Management's largest Q1 2023 buy was Teva Pharmaceuticals: 762,264 shares worth $6.75M.
- Endurant Capital Management added most to BioMarin Pharmaceuticals in Q1 2023, an estimated $17.8M increase.
- Endurant Capital Management's biggest Q1 2023 reduction was Labcorp, cutting an estimated $10.9M.
- Endurant Capital Management fully exited Elutia in Q1 2023, selling an estimated $5.35M.
- Endurant Capital Management's ten largest holdings make up 61% of its $195M portfolio in Q1 2023.
- Endurant Capital Management opened 17 new positions and closed 22 in Q1 2023.
- Endurant Capital Management's portfolio value fell 21% quarter-over-quarter to $195M.
Based on Endurant Capital Management's 13F filing for Q1 2023, filed 15 May 2023.